Gene Solutions and Element Biosciences Partner to Transform Next-Generation Sequencing Globally
On April 22, 2025, a significant collaboration was formalized between Gene Solutions, a prominent name in biotechnology and advanced genetic testing, and Element Biosciences, a revolutionary company known for democratizing access to advanced life-science solutions. The signing of a Memorandum of Understanding (MoU) took place at Gene Solutions' laboratory in Ho Chi Minh City, marking a pivotal point for both institutions as they join forces to create groundbreaking synergies.
The core objective of this partnership is to merge Element Biosciences' leading-edge sequencing platforms with Gene Solutions' innovative technologies in genetic solutions, thereby establishing a powerful collaborative framework. Element has rapidly made its mark as a preeminent innovator in the next-generation sequencing (NGS) arena, granting scientists and researchers groundbreaking solutions characterized by excellent performance and flexibility.
Gene Solutions, which already boasts a comprehensive portfolio of genetic tests, has been leveraging NGS technology along with artificial intelligence to reach an impressive network of over 4,500 hospitals and clinics across eight Asian nations. This strategic collaboration aims not just at geographical expansion but is also oriented toward making advanced genetic testing more accessible worldwide.
Non-Invasive Prenatal Testing and Reproductive Health
Among the most recognized applications of NGS technology is the Non-Invasive Prenatal Testing (NIPT), which screens for genomic abnormalities through cell-free DNA from the placenta found in the mother’s bloodstream. This test is typically recommended to all pregnant women from 9-10 weeks of gestation. Over the past several years, Gene Solutions developed triSure™, a solid brand in NIPT solutions alongside its extensive ecosystem for reproductive health, catering from prenatal to postnatal diagnostics.
Furthermore, Gene Solutions is innovating the NIPT process by integrating screenings for recessive diseases and dominant single-gene disorders in a streamlined procedure. Current developments also include the potential incorporation of pregnancy complication predictions into routine testing. The global market for NIPT is projected to surge from USD 5.20 billion in 2022 to an impressive USD 19.09 billion by 2030, indicating a growing demand for such efficient testing solutions.
Advancing Cancer Care Through Precision Oncology
An additional focus of Gene Solutions has been on precision oncology, emphasizing the necessity of early cancer detection—which is often vital for successful intervention. The company has deployed its AI-driven, clinically validated SPOT-MAS test, which has shown promise in identifying cancers early, including those for which traditional screening methods have yet to be established.
By combining genomic and transcriptomic tumor profiling, Gene Solutions aids cancer patients in selecting targeted therapies and immunotherapies, while concurrently offering personalized cancer monitoring through platforms such as K-TRACK and K-4CARE. The collaboration with Element Biosciences is designed to propel this research further, ensuring Gene Solutions' tools are effectively integrated into clinical practices around the globe.
Introducing AVITI24™ for Genomics Research
A game-changer, Element Biosciences' AVITI24™ multiomics platform stands at the forefront of their technological capabilities. In addition to providing precise NGS readouts, AVITI24 is equipped to conduct simultaneous transcriptomic, proteomic, and morphological profiling at a single-cell level. The platform’s proprietary avidite base chemistry (ABC) sequencing fuels dynamic insights into complex biological mechanisms, aiding researchers in making breakthroughs that translate to real-world health benefits.
Gene Solutions plans to utilize AVITI24 in vital research pipelines, including clinical multi-omics projects and the development of patient-derived organoids, which are essential for advancing new cancer treatments. This means that researchers can look forward to gaining unified multidimensional data that has previously been elusive.
Future of Genomic Solutions
Dr. Nguyen Huu Nguyen, the Deputy CEO at Gene Solutions, expressed his optimism regarding the collaboration, stating that the partnership is set to revolutionize accessibility and application of genomic innovations throughout the industry. Meanwhile, Edwin Hauw, Senior Vice President at Element Biosciences, emphasized that the synergies between both companies will significantly impact researchers and clinician-patient interactions.
This MoU opens doors for further discussions on strategic partnerships, technical support, marketing efforts, and research elements, framing a cooperative roadmap aimed at boosting global strategies in genomics. The fusion of Gene Solutions' vast expertise and market reach with Element Biosciences' revolutionary capabilities in sequencing technology heralds a new chapter in genetic testing that prioritizes accessibility and transformative healthcare solutions for all.
The core objective of this partnership is to merge Element Biosciences' leading-edge sequencing platforms with Gene Solutions' innovative technologies in genetic solutions, thereby establishing a powerful collaborative framework. Element has rapidly made its mark as a preeminent innovator in the next-generation sequencing (NGS) arena, granting scientists and researchers groundbreaking solutions characterized by excellent performance and flexibility.
Gene Solutions, which already boasts a comprehensive portfolio of genetic tests, has been leveraging NGS technology along with artificial intelligence to reach an impressive network of over 4,500 hospitals and clinics across eight Asian nations. This strategic collaboration aims not just at geographical expansion but is also oriented toward making advanced genetic testing more accessible worldwide.
Non-Invasive Prenatal Testing and Reproductive Health
Among the most recognized applications of NGS technology is the Non-Invasive Prenatal Testing (NIPT), which screens for genomic abnormalities through cell-free DNA from the placenta found in the mother’s bloodstream. This test is typically recommended to all pregnant women from 9-10 weeks of gestation. Over the past several years, Gene Solutions developed triSure™, a solid brand in NIPT solutions alongside its extensive ecosystem for reproductive health, catering from prenatal to postnatal diagnostics.
Furthermore, Gene Solutions is innovating the NIPT process by integrating screenings for recessive diseases and dominant single-gene disorders in a streamlined procedure. Current developments also include the potential incorporation of pregnancy complication predictions into routine testing. The global market for NIPT is projected to surge from USD 5.20 billion in 2022 to an impressive USD 19.09 billion by 2030, indicating a growing demand for such efficient testing solutions.
Advancing Cancer Care Through Precision Oncology
An additional focus of Gene Solutions has been on precision oncology, emphasizing the necessity of early cancer detection—which is often vital for successful intervention. The company has deployed its AI-driven, clinically validated SPOT-MAS test, which has shown promise in identifying cancers early, including those for which traditional screening methods have yet to be established.
By combining genomic and transcriptomic tumor profiling, Gene Solutions aids cancer patients in selecting targeted therapies and immunotherapies, while concurrently offering personalized cancer monitoring through platforms such as K-TRACK and K-4CARE. The collaboration with Element Biosciences is designed to propel this research further, ensuring Gene Solutions' tools are effectively integrated into clinical practices around the globe.
Introducing AVITI24™ for Genomics Research
A game-changer, Element Biosciences' AVITI24™ multiomics platform stands at the forefront of their technological capabilities. In addition to providing precise NGS readouts, AVITI24 is equipped to conduct simultaneous transcriptomic, proteomic, and morphological profiling at a single-cell level. The platform’s proprietary avidite base chemistry (ABC) sequencing fuels dynamic insights into complex biological mechanisms, aiding researchers in making breakthroughs that translate to real-world health benefits.
Gene Solutions plans to utilize AVITI24 in vital research pipelines, including clinical multi-omics projects and the development of patient-derived organoids, which are essential for advancing new cancer treatments. This means that researchers can look forward to gaining unified multidimensional data that has previously been elusive.
Future of Genomic Solutions
Dr. Nguyen Huu Nguyen, the Deputy CEO at Gene Solutions, expressed his optimism regarding the collaboration, stating that the partnership is set to revolutionize accessibility and application of genomic innovations throughout the industry. Meanwhile, Edwin Hauw, Senior Vice President at Element Biosciences, emphasized that the synergies between both companies will significantly impact researchers and clinician-patient interactions.
This MoU opens doors for further discussions on strategic partnerships, technical support, marketing efforts, and research elements, framing a cooperative roadmap aimed at boosting global strategies in genomics. The fusion of Gene Solutions' vast expertise and market reach with Element Biosciences' revolutionary capabilities in sequencing technology heralds a new chapter in genetic testing that prioritizes accessibility and transformative healthcare solutions for all.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.